Boston Scientific Co. (NYSE:BSX) is Holocene Advisors LP’s 6th Largest Position

Holocene Advisors LP lowered its position in Boston Scientific Co. (NYSE:BSX) by 1.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,997,632 shares of the medical equipment provider’s stock after selling 42,798 shares during the period. Boston Scientific makes up about 1.4% of Holocene Advisors LP’s portfolio, making the stock its 6th largest position. Holocene Advisors LP owned approximately 0.27% of Boston Scientific worth $335,002,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BSX. Triad Wealth Partners LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Values First Advisors Inc. acquired a new stake in Boston Scientific in the 3rd quarter worth approximately $28,000. Andra AP fonden purchased a new stake in Boston Scientific during the 2nd quarter worth approximately $29,000. Lynx Investment Advisory acquired a new position in Boston Scientific during the 2nd quarter valued at approximately $30,000. Finally, E Fund Management Hong Kong Co. Ltd. purchased a new position in shares of Boston Scientific in the third quarter worth $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX stock opened at $90.66 on Monday. The company has a market capitalization of $133.62 billion, a P/E ratio of 74.93, a P/E/G ratio of 2.67 and a beta of 0.79. Boston Scientific Co. has a 12-month low of $53.93 and a 12-month high of $91.93. The business’s 50 day moving average is $86.70 and its two-hundred day moving average is $80.80. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business’s revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.50 EPS. Analysts expect that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BSX shares. TD Cowen boosted their price objective on shares of Boston Scientific from $86.00 to $100.00 and gave the company a “buy” rating in a report on Monday, October 21st. Evercore ISI boosted their price target on Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Wells Fargo & Company raised their price objective on Boston Scientific from $87.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, October 24th. Morgan Stanley upped their target price on Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research report on Thursday, October 24th. Finally, Bank of America raised their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $93.39.

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares in the company, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 328,157 shares of company stock valued at $27,894,270 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.